Lv2
140 积分 2024-10-22 加入
DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial
14天前
已完结
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
17天前
已完结
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
17天前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
19天前
已完结
Macrophages in intestinal homeostasis and inflammatory bowel disease
19天前
已完结
IBD disease-modifying therapies: insights from emerging therapeutics
19天前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
28天前
已完结
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
28天前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
1个月前
已完结
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
1个月前
已完结
皖公网安备34019202002308
